SHERIDAN, WYOMING – NOVEMBER 09, 2024 – FUJIFILM Diosynth Biotechnologies, a leading Contract Development and Manufacturing Organization (CDMO) specializing in biologics, vaccines, advanced therapies, and oncolytic viruses, has announced the completion of the first phase of its expansion project at its Hillerød, Denmark site. This achievement is a significant milestone in the company's plan to establish a global network of facilities dedicated to improving the manufacturing and delivery of life-saving medications.
The first phase of the expansion project has resulted in the addition of six mammalian cell bioreactors, increasing the total capacity at the Hillerød site to an impressive 12 x 20,000 L bioreactors. The next phase, backed by a substantial capital investment, will see the addition of 8 x 20,000 L bioreactors and two downstream processing streams.
By mid-2025, fill/finish production is expected to commence, with the full expansion plan slated for completion by 2026. This expansion will increase the site's footprint to approximately 51,500 sq meters and is projected to create up to 2,200 jobs.
"Our operations in Hillerød represent our commitment to being the world-leading partner for life supporting our customers and their patients globally," said Christian Houborg, Site Head and Senior Vice President of FUJIFILM Diosynth Biotechnologies. "This expansion is a testament to our vision for introducing robust capabilities into the global biopharma landscape, ensuring the timely delivery of critical therapies to those in need."
Since 2011, FUJIFILM Corporation has invested over $8 billion in biologics manufacturing, which includes strategically located facilities designed for rapid production scaling. In 2025, operations will begin at a new, large-scale facility in Holly Springs, North Carolina, further solidifying the company's commitment to expanding its global presence.
"With our Partners for Life strategy, we are dedicated to fulfilling our promises and ensuring that our global network supports the production of the life-impacting medicines that make patients' lives better," added Lars Petersen, Global Head of Business Development, FUJIFILM Diosynth Biotechnologies.
This expansion project is in line with the company's sustainability initiative, Partners for the Planet, which promotes sustainable practices across all its facilities. The Hillerød site has signed a 10-year Power Purchase Agreement (PPA) to source all its electricity from renewable sources, contributing to its silver certification from the globally recognized EcoVadis standard.
A PPA is a long-term contract between an electricity generator and an electricity consumer for the production and consumption of electricity. The generator is responsible for building, operating, and maintaining the power generation facility, while the customer agrees to purchase the electricity generated. PPAs are frequently used in the development of new renewable energy projects, which are often situated away from the consumer's premises and delivered through the public electricity grid.
FUJIFILM Diosynth Biotechnologies' expansion project is a testament to the company's dedication to enhancing the production and delivery of life-saving medications. By expanding its global network of facilities and incorporating sustainable practices, FUJIFILM Diosynth Biotechnologies is well-positioned to meet the evolving needs of its partners and the patients they serve.